Riskpilot← Back to searchSign inGet full accessImmunoWise AB
ABActiveOrg 5566932918SollentunaResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20050 employees
Revenue 2025
SEK 360K
-67% vs 2024
EBITDA margin
-341.0%
+82% vs 2024
Equity ratio
18.4%
Financial strength
Net profit 2025
SEK -11,4M
-206% vs 2024
| Revenue | SEK 360K | -67% |
| EBITDA | SEK -1,2M | +82% |
| Net profit | SEK -11,4M | -206% |
| Total assets | SEK 1,6M | -88% |
| Equity | SEK 293K | -97% |
| Employees | 0 | — |
Legal name
ImmunoWise AB
Org number
5566932918
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9 december 2005
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska erbjuda konsulttjänster för utveckling och etablering av nya terapier och bolag, samt konsultverksamhet inom immunologisk behandling, utbildning, utveckling och forskning samt bioteknik och därmed förenlig verksamhet. Bolaget ska dessutom investera i och förvalta fastigheter samt aktier i onoterade och noterade bolag och därmed förenlig verksamhet.
Address
Sollentuna
Email
abbe@ekonomilanken.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 885 | 2 125 | 1 280 | 1 232 | 360 | 0 | 1 110 | 1 080 | 360 |
| Staff expenses | — | — | — | — | — | — | — | — | −0 | — | — | −137 |
| EBITDA | 57 | 791 | −218 | 216 | 1 260 | 388 | −4 083 | −353 | 0 | −6 168 | −6 693 | −1 228 |
| Depreciation & amort. | −24 | −11 | −12 | −10 | −6 | −4 | −4 | −1 | −0 | −0 | −0 | — |
| EBIT | 33 | 780 | −230 | 206 | 1 254 | 384 | −4 087 | −354 | 0 | −6 168 | −6 693 | −1 228 |
| Net financials | −235 | — | −384 | — | −558 | 180 | 10 571 | 17 660 | 0 | 15 176 | 17 636 | −10 460 |
| Profit before tax | −202 | 631 | −405 | 155 | 657 | 533 | 6 654 | 17 405 | 0 | 15 465 | 10 849 | −11 373 |
| Tax | 20 | −118 | −2 | −44 | −209 | −109 | −115 | −34 | −0 | −0 | −90 | −9 |
| Net profit | −182 | 513 | −407 | 111 | 448 | 424 | 6 539 | 17 371 | 0 | 15 465 | 10 759 | −11 381 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 790 | 1 627 | 825 | 923 | 2 045 | 2 893 | 9 098 | 26 483 | 9 098 | 22 296 | 13 125 | 1 589 |
| Equity | 499 | 862 | 454 | 470 | 918 | 1 342 | 7 880 | 25 251 | 7 880 | 20 716 | 11 475 | 293 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 185 | 185 | 185 | 185 | 0 | 625 | 100 |
| Short-term debt | 232 | 556 | 371 | 402 | 761 | 831 | 497 | 511 | 497 | 674 | 396 | 167 |
| Total debt | 232 | 556 | 371 | 402 | 761 | 1 016 | 682 | 696 | 682 | 674 | 1 021 | 267 |
EBITDA margin
-341.0%
This company
15.8%
Market median
-2258% vs market
20152025
Equity ratio
18.4%
This company
38.2%
Market median
-52% vs market
20152025
Return on equity
-3883.1%
This company
18.4%
Market median
-21204% vs market
20152025
Net profit margin
-3161.5%
This company
8.1%
Market median
-39131% vs market
20152025
Asset turnover
0.23×
This company
1.12×
Market median
-79% vs market
20152025
Debt / equity
4.42×
This company
0.62×
Market median
-613% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AC | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ImmunoWise AB 
Tinnovate ABBoard members of ImmunoWise AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Cecilia Grimslätt | Audit | 0 companies |
| Eva Monica Plyhm | Deputy Board Member | 0 companies |
| Stig Jonas Winqvist | Board of Directors | 0 companies |
| Stig Ola Winqvist | Chairman | 0 companies |